The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, L.-F.
Right arrow Articles by Ting, J. P.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, L.-F.
Right arrow Articles by Ting, J. P.-Y.
The Journal of Immunology, 2000, 164: 2769-2775.
Copyright © 2000 by The American Association of Immunologists

IL-8 Reduced Tumorigenicity of Human Ovarian Cancer In Vivo Due to Neutrophil Infiltration1

Li-Fen Lee2,*,{dagger}, Ronald P. Hellendall{dagger}, Ying Wang{dagger}, J. Stephen Haskill*,{dagger}, Naofumi Mukaida{ddagger}, Kouji Matsushima{ddagger} and Jenny P.-Y. Ting3,*,{dagger}

* Departments of Biology, Microbiology-Immunology, and Obstetrics and Gynecology and {dagger} Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599; and {ddagger} Department of Pharmacology and § Cancer Research Institute, Kanazawa University, Kanazawa, Japan

Paclitaxel is a frontline therapy for ovarian cancer. Our laboratory has shown that paclitaxel induces IL-8, a member of the C-X-C family of chemokines, in subsets of human ovarian cancer cells. However, the critical issue concerns the biological significance of this chemokine in human ovarian cancer. To study the influence of IL-8 on tumor growth, human ovarian cancer cell lines were transfected with an expression vector for human IL-8 and tested for their ability to form tumors in nude mice. IL-8 expression by the transfected cells did not alter their growth properties in vitro. In contrast, tumor growth in vivo was significantly attenuated in animals receiving IL-8-expressing cells when compared with mice injected with control cells. As additional evidence that IL-8 is a crucial factor in tumor growth, it was noted that ovarian cell lines in which constitutive IL-8 expression is elevated did not form tumors. Injection of neutralizing Ab to IL-8 reverted the phenotype and caused tumor growth in vivo. Examination of tissue from the inoculation site revealed a dramatically elevated cellularity, containing neutrophils and macrophages, in mice receiving IL-8-expressing tumor cells. These results suggest that IL-8 production by human ovarian tumor cells can play a role in reducing the rate of tumor growth; this effect may be mediated by the increased targeting of neutrophil and other mononuclear cells to the tumor injection site. These studies indicate a role for IL-8 in ovarian cancer control and suggest that chemotherapy-induced IL-8 may have a positive role in controlling tumor growth.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
S. R. Perri, D. Martineau, M. Francois, L. Lejeune, L. Bisson, Y. Durocher, and J. Galipeau
Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways
Mol. Cancer Ther., February 1, 2007; 6(2): 441 - 449.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. E. De Larco, B. R. K. Wuertz, and L. T. Furcht
The Potential Role of Neutrophils in Promoting the Metastatic Phenotype of Tumors Releasing Interleukin-8
Clin. Cancer Res., August 1, 2004; 10(15): 4895 - 4900.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
N. Mukaida
Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases
Am J Physiol Lung Cell Mol Physiol, April 1, 2003; 284(4): L566 - L577.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. Hu, J. Hofmann, C. Zaloudek, N. Ferrara, T. Hamilton, and R. B. Jaffe
Vascular Endothelial Growth Factor Immunoneutralization Plus Paclitaxel Markedly Reduces Tumor Burden and Ascites in Athymic Mouse Model of Ovarian Cancer
Am. J. Pathol., November 1, 2002; 161(5): 1917 - 1924.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Salcedo, M. Martins-Green, B. Gertz, J. J. Oppenheim, and W. J. Murphy
Combined Administration of Antibodies to Human Interleukin 8 and Epidermal Growth Factor Receptor Results in Increased Antimetastatic Effects on Human Breast Carcinoma Xenografts
Clin. Cancer Res., August 1, 2002; 8(8): 2655 - 2665.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
K. Kawakami, M. Kawakami, P. J. Snoy, S. R. Husain, and R. K. Puri
In Vivo Overexpression of IL-13 Receptor {alpha}2 Chain Inhibits Tumorigenicity of Human Breast and Pancreatic Tumors in Immunodeficient Mice
J. Exp. Med., December 17, 2001; 194(12): 1743 - 1754.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. M. Cairns, J. R. Gordon, F. Li, M. E. Baca-Estrada, T. Moyana, and J. Xiang
Lymphotactin Expression by Engineered Myeloma Cells Drives Tumor Regression: Mediation by CD4+ and CD8+ T Cells and Neutrophils Expressing XCR1 Receptor
J. Immunol., July 1, 2001; 167(1): 57 - 65.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
H. Zhang, S. Wei, J. Sun, D. Coppola, B. Zhong, G. D. Wu, B. Goodwin, S. Sebti, J. Y. Djeu, and G. Blanck
Retinoblastoma Protein Activation of Interleukin 8 Expression Inhibits Tumor Cell Survival in Nude Mice
Cell Growth Differ., December 1, 2000; 11(12): 635 - 639.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
S. Huang, J. B. Robinson, A. DeGuzman, C. D. Bucana, and I. J. Fidler
Blockade of Nuclear Factor-{{kappa}}B Signaling Inhibits Angiogenesis and Tumorigenicity of Human Ovarian Cancer Cells by Suppressing Expression of Vascular Endothelial Growth Factor and Interleukin 8
Cancer Res., October 1, 2000; 60(19): 5334 - 5339.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.